Top Markets
#1 Black Phoenix Black Phoenix +355.83%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +56.22%
#4 Akedo Akedo +47.65%
#5 Acurast Acurast +37.50%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.68%
#7 BasedHype BasedHype +26.37%
#8 Cryptopia Cryptopia +21.54%
#9 Avantis Avantis +21.14%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +15.55%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Immatics biotechnologies GmbH Immatics biotechnologies GmbH

Immatics biotechnologies GmbH

IMTXW
Classifica tra le azioni #40868
Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to... Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T cell-redirecting immunotherapies designed to combat cancer, primarily targeting the United States market for treatment applications. Their research and development efforts are concentrated on creating targeted immunotherapies for solid tumors, employing two distinct therapeutic strategies: adoptive cell therapies (ACTs) and antibody-like T-cell receptor (TCR) Bispecifics. Immatics N.V. boasts a robust pipeline of product candidates. Among these are IMA203, an immunotherapy targeting solid tumors, and IMA203CD8, a cell therapy product, both currently undergoing Phase 1b clinical trials. Additionally, their earlier-stage assets include IMA204, designed to target tumor stroma, and IMA30x, an allogeneic cellular therapy candidate, both of which are in preclinical development. The company is also progressing with its TCR Bispecifics portfolio, featuring IMA401 in Phase 1b clinical trials, alongside IMA402 and IMA403, which are presently in preclinical phases. Furthermore, Immatics N.V. has established strategic alliances to bolster its development efforts. These include a partnership with MD Anderson Cancer Center for the advancement of various T cell and TCR-based adoptive cellular therapies, an agreement with Celgene Corporation focused on creating innovative adoptive cell therapies for diverse cancers, and a collaboration with Genmab A/S aimed at developing T cell-engaging bispecific immunotherapies for multiple oncological indications. The company's corporate headquarters are situated in Tübingen, Germany.
Prezzo delle azioni
$0.0006
Ultima sincronizzazione: 2025-06-30
Capitalizzazione di mercato
$69.91K
Variazione (1 giorno)
-88.46%
Variazione (1 anno)
0.00%
Paese
US
Scambia Immatics biotechnologies GmbH (IMTXW)

Categoria

Healthcare
Storico del prezzo dell'azione per Immatics biotechnologies GmbH (IMTXW)
Prezzo di chiusura più alto: $0.01 il 2025-06-01

Prezzo di chiusura più basso: $3.85 il 2020-07-01
Storico del prezzo dell'azione di Immatics biotechnologies GmbH dal 2020 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2025 -95.05%
2024 -89.61%
2023 3.46%
2022 -27.40%
2021 31.37%
2020 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $522.05 31.86%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $863.30 33.51%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $744.96 8.94%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.08K -6.68%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $259.89 16.65%
BE